As of the third quarter, our year-to-date gross profit in our care solutions segment is $4.6 million. Operating income was negatively impacted by certain one-time items related to our relationship with Babylon. However, adjusted for the impact of the Babylon related items in our year-to-date care solutions operating income is approximately breakeven. Enterprise adjusted EBITDA was $1.2 million in the third quarter and it is $1.9 million on a year-to-date basis. We would note that enterprise adjusted EBITDA includes significant corporate operating costs. And consumer care when combining the care delivery and care solutions segments, our adjusted EBITDA before corporate expenses was more than $12 million in the third quarter and approximately $36 million for the year-to-date period.
We have taken action in the fourth quarter to reduce corporate operating expenses, rightsizing our corporate operations for the go-forward business, which we expect to support enterprise adjusted EBITDA in 2024. We currently plan to provide 4.24 guidance to gel with the release of our fourth quarter results. Turning to the ACA insurance business wind-down, while we continue to make significant progress in third quarter. As of today, we believe we are more than 98% complete on medical claims in the ACA insurance business. Our medical claims expense in the quarter was slightly higher than our prior forecast. On September 9, we announced the Bright Health paid $1.5 billion to the Centers for Medicare and Medicaid Services satisfying 80% of the final ACA insurance business risk adjustment obligations.
We also announced that our insurance subsidiaries in Colorado, Florida, Illinois and Texas, entered into repayment agreements for a principal amount of $380 million with CMS with respect to the unpaid amount of risk adjustment obligations. The principal amount and repayment agreements is due in 18 months from September 15, 2023, and bears interest at a 11.5%. As of the end of the third quarter, our ACA insurance business had $289 million in regulatory capital. Net of our forecast for remain — remaining medical costs and other anticipated operating and wind-down costs. We expect to have $220 million in excess capital that we will look to work with the state regulators to recover, including approximately $1.5 million in the markets with repayment agreements and approximately $115 million in the other markets where we have excess regulatory capital.
In total excess regulatory capital netted against the $380 million principal of the repayment obligation results in a net risk adjustment obligation of approximately $160 million before interest costs. Now looking at our balance sheet. As of the end of the third quarter, we had $735 million in total cash investments, including amounts in our regulated entities. Our non-regulated cash and short-term investments were $113.6 million as of the end of Q3. We had $303.9 million drawn in our $350 million bank facility and $30.7 million in letters of credit on this facility committed to supporting our participation in ACO Reach program. We also announced during the quarter that we entered into a new supplemental credit agreement with NEA for $60 million, which was later expanded by $6.4 million with a new lender.
As of September 30, we had $50 million borrowed on this credit agreement. This financing is expected to support the working capital needs of the company pending the close of the California Medicare Advantage business sales moving on. As Mike noted, we continue to work through the regulatory approvals for the sale of our California Medicare Advantage business, which we announced on June 30. We continue to expect to close the transaction by the first quarter of 2024. We expect the proceeds to bolster our balance sheet including potential uses such as paying down the ACA insurance business risk adjustment obligations, paying down our credit facility borrowings and general corporate users. We’ve adjusted our full year 2023 outlook this morning with our new revenue outlook, largely reflecting a tweak to the benchmark forecast for the ACO Reach business, which is offset by our lower medical cost forecast.
